Abstract
BACKGROUND:
Hepatitis B virus (HBV) accounts for more than 60% of hepatocellular carcinoma (HCC) cases. However, there is limited information about the features of HBV-driven HCC that differentiate it from other types of HCC.
OBJECTIVE:
The aim of this study is to find a gene specific to HBV-driven HCC and understand its role during tumorigenesis.
METHODS:
The differences in gene expression patterns were analyzed among patients with hepatitis virus-unrelated liver cirrhosis, and hepatitis C virus- and HBV-driven HCC. Genes expressed only in HBV patients were compared to genes of transgenic mice expressing hepatitis B viral X gene.
RESULTS:
Integrin
CONCLUSIONS:
This study found a significant association between HBV and integrin
Introduction
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third leading cause of cancer death in the world [1]. More than 70% of newly diagnosed HCC cases are in Asia due to poor hygiene, many carriers of chronic hepatitis B and C virus infection, and vertical transmission [2]. Although the use of alcohol, metabolic diseases, and non-alcoholic fatty liver disease are increasingly found to be causes of HCC, chronic hepatitis is still responsible for the majority of HCC cases [3]. Hepatitis B virus (HBV)-driven HCC accounts for more than 60% of all HCC cases [4].
Due to biological differences between HBV, a DNA virus, and hepatitis C virus (HCV), an RNA virus, different genomic factors affect their impact on HCC formation and progression [4]. Also, HCCs induced by non-viral causes have different genomic expression than hepatitis virus-driven HCC. However, diverse biomarkers for hepatocellular carcinoma, such as membrane-type 1 matrix metalloproteinase, hepatocyte growth factor, c-met, proline-rich tyrosine kinase 2, and transforming growth factor-
Hepatitis B viral X protein (HBx) is a key viral regulatory protein and is associated with carcinogenesis among chronic hepatitis B carriers [9, 10, 11]. HBx interacts with p53 to suppress its tumor suppressive role, and augments anti-apoptotic signaling, such as the Ras pathway, and pro-survival transcription factors [12, 13, 14]. Thus, animals who express HBx more susceptible to hepatocellular carcinoma [15, 16]. As the HBx gene is prone to mutations which cause functional change, its cellular roles are likely to be more variable than what has been verified so far [17, 18]. Since HBx plays a critical role in HBV-driven HCC, we focused on finding a novel target related to HBx. Additionally, we validated the potential of the novel target for predicting invasiveness and prognosis of HBV-driven HCC specifically. We also validated the effectiveness of the novel biomarker in laboratory animals and HCC cells.
Materials and methods
Cell culture
Two HCC cell lines, HepG2 and Hep3B, were purchased from Korea Cell Bank (Seoul, Korea). The cells were cultured in RPMI 1640 (Hyclone, Logan, UT, USA) with 10% fetal bovine serum (Hyclone, Logan, UT, USA), 200
DNA, RNA, and siRNA information
HBx plasmids were provided by Dr. Eun Young Cho (Wonkwang University, Korea). A 269-bp fragment of the X gene was amplified using the primer set 5’-GGAGTTGGGGGAGGAGAT-3’ (forward) and 5’-TCCCCTTCTTCATCTCCC-3’ (reverse). siRNA specific for ITGA6 was made using the primers: 5’-AGCCTCTTCGGCTTCTCG-3’ (forward), 5’-TTG GCTTCTGCAGTGGAA-3’ (reverse). Real-time quantitative PCR was performed using TaqMan 7500 (Applied Biosystems, Foster City, CA, USA). mRNA levels were measured using the SYBR Green I assay with SYBR Green Universal PCR Master Mix, according to the manufacturer’s instructions (Applied Biosystems). Human GAPDH was used as the housekeeping gene and each reaction was run in triplicate. The expression levels of transcripts were calculated by the relative quantification (
Gene expression analysis of HCC
Differentially expressed gene (DEG) profiles were retrieved from the Gene Expression Omnibus (GEO) database at the National Center for Biotechnology Information (NCBI). The gene profiles of non-HBV cirrhosis, HCV-driven HCC, and HBV-driven HCC were taken from entries GSE25097, GSE44074, and GSE47197 in the GEO database, respectively. Microarray data on the HBx mouse group was provided by Dr. Dae Ho Lee (Gachon University, Korea) [19]. Genes whose expression increased more than two-fold were selected. The gene network was analyzed in Cytoscape (version 3.0.0), which is connected to the databases mantha, I2D, and IntAct. For enrichment of the transcriptome, we used a transcription factor list from Uhlén et al. [20] and for membrane protein enrichment, database FANTOM5.
Western blot
Cells were lysed at 4
Immunoprecipitation
Cells were disrupted in a lysis buffer of 0.5% Triton X-100, 0.1% SDS, and a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA). Then, the lysates were centrifuged at 15,000
Schematic of meta-data analysis. (A) Public human cohort data were collected and meta-analyzed. (B) The data were compared with animal data. (C) The enriched gene sets predict the role of genes in the disease. (D) Subsequent 
Differentially expressed gene (DEG) patterns. (A) Venn diagrams showing the DEG patterns among hepatitis virus-unrelated liver cirrhosis, hepatitis C virus-driven hepatocellular carcinoma, and hepatitis B virus-driven hepatocellular carcinoma patients. Three genes were commonly upregulated and 7 genes were commonly downregulated in three patient groups. DEGs were identified using a cutoff of a two-fold change. (B) Venn diagrams showing the DEG patterns between hepatitis B virus-driven hepatocellular patients and transgenic mice expressing the hepatitis B viral X gene. Thirteen upregulated genes and 28 downregulated genes were shared between HBV-driven HCC patients and HBX gene expressing transgenic mice. DEGs were identified using a cutoff of a two-fold change.
Formalin-fixed paraffin-embedded liver blocks from HBx homozygous transgenic (HBxTg) mice that have one copy of HBx transgene on chromosome 2 were given by Drs Cho (Wonkwang University, Korea) and Lee (Gachon University, Korea). The details about the development and the characteristics of HBxTg mice has been described previously [21]. The strain of HBxTg mice was fixed to C57BL/6 by backcrossing with the C57BL/6 strain for more than 20 generations. HBx
The embedded tissues (5 mm
Cell migration assay
Cell migration was analyzed using 24-well transwell chambers with polycarbonate membranes (8.0-
Enrichment of differentially expressed genes (DEGs) with transcription factors or membrane proteins. Venn diagram of DEGs enriched with (A) transcription factors or (B) membrane proteins. There was no overlap of transcription factors between HBx transgenic mice and HBV-driven HCC (red dotted circle). Three membrane protein genes, which were closely related to cancer invasion and initiation of cellular signaling, were shared between HBx transgenic mice and HBV-driven HCC (red dotted circle).
Collection of HCC-related human and animal data
Many sets of gene expression data for particular diseases have accumulated in the last 20 years. As surgical resection and biopsy are performed for most types of cancer, tissue samples are collected and their related gene expression data sets provide statistically reliable information. The analysis of expression patterns is effective for finding a gene marker for a disease (Fig. 1A). It can be compared with animal data of same disease (Fig. 1B). This comparison may indicate a mode of action of the target gene. Additionally, the gene can be categorized based on ontology, so the gene-associated signaling pathway, cellular location, and the other characteristics can provide clues about the gene function (Fig. 1C). Subsequent
DEG profiles of non-HBV liver cirrhosis, HCV-driven HCC, and HBV-driven HCC patients, and HBx mice
We searched for gene expression patterns of non-HBV cirrhosis, HCV-driven HCC, and HBV-driven HCC groups in the GEO database (Fig. 2A). As tumor growth-related factors of HBV-driven HCC are expected to show differences from HCV-related factors, we focused our analysis on the HBV-driven HCC group. Though the HBV-driven HCC group shared 4 and 41 overexpressed genes with the HCV-driven HCC group and non-HBV cirrhosis group, respectively, 88 genes were overexpressed only in the HBV-driven HCC group. Because HBx augments tumor malignancy, the relationship between HBx and HBV-driven HCC was revealed by comparing the gene profiles of the HBV-driven HCC group in the GEO database and HBx transgenic mice (Fig. 2B). DEGs were identified using a cutoff two-fold change. Integrin
Ontology-based marker study
The HBV induced network in HCC was significantly different from the network in other types of HCC (Fig. S1). There were many more nodes between genes compared with HCV-driven HCC. Transcription factors and membrane proteins or receptors are generally considered upstream driver genes rather than passenger genes in a disease. The DEG lists were enriched with transcription factors and membrane proteins separately. In the transcription factor enrichment analysis, a large portion showed an independent pattern with little or no overlap among the two HCC, one HBx-transgenic liver, and one cirrhosis group. There is no overlap in transcription factors between HBx transgenic and HBV related cancer groups. On the other hand, genes of membrane proteins overlapped among the four groups (Fig. 3). Membrane proteins are important for interaction with the extracellular matrix during cancer progression and initiate outside-in cellular signaling.
Association between hepatitis B viral X and integrin 
Increased expression of ITGA6 in HBxTg mouse liver tissue. (A) The mRNA level of ITGA6 in WT and HBxTg mice was validated by RT-PCR. (B) Real-Time PCR was performed to compare wild type and HBxTg mice. *
HBx was transfected into Hep3B cells, human HBV infected hepatocytes, and HepG2 cells, well-differentiated human HCC cells not infected with HBV. Post transfection, mRNA and protein levels of ITGA6 were monitored by PCR and western blot, respectively. ITGA6 was slightly downregulated 1 week after transfection. Then, it was gradually upregulated until week 4 without affecting the 67 kDa laminin receptor, a nonintegrin laminin receptor in Hep3B (Fig. 4A and B) and HepG2 cells (Fig. 4C and D). As the expression of HBx increased, the expression of ITGA6 increased. Additionally, integrin
The increased ITGA6 expression was confirmed in liver tissue isolated from HBx transgenic mice. The RT-PCR experiment showed a slightly increased pattern of ITGA6 in HBxTg compared with the wild type control (Fig. 5A). Real-Time PCR showed a significant difference between two groups (Fig. 5B).
The influence of laminin and hepatitis B viral X on hepatocytes. Laminin and HBx induced cellular migration in (A, B) Hep3B cells and (C, D) HepG2 cells. FOV: field of view; EV: empty vehicle; LN: laminin; HBx: hepatitis B viral X; NS: non-specific *
Influence of hepatitis B viral X and effects of siRNA specific for ITGA6 on inhibition of proliferation. siRNA specific for ITGA6 reduced the migration ability of HBx-transfected cells to pre-HBx transfection levels in (A) Hep3B and (B) HepG2 cells. The inhibitory effect of siRNA specific for ITGA6 in (B) HEP3B cells was not significant. The inhibitory effect of siRNA specific for ITGA6 in (D) HEPG2 cells was significant. ITGA6: integrin 
Administration of laminin induced migration of Hep3B and HepG2 cells (Fig. 6). The migration was significantly different between the laminin treated and control cells. In both cell lines, transfection with HBx resulted in more pronounced migration. The rate of migration of HepG2 cells was more significant than that of Hep3B cells. In addition, laminin administration and HBx transfection had strong synergistic effects on cellular migration.
Effects of ITGA6 suppression on the migration of HCC cells
As we found, HBx increased cellular migration in both cell lines (Fig. 7A–D, middle panels). Nevertheless, siRNA specific for ITGA6 reduced the migration ability of HBx-transfected cells to pre-HBx transfection levels (Fig. 7A–D, right panels; Fig. S2). The inhibitory effects of siRNA specific for ITGA6 were more prominent in HepG2 cells. In HepG2 cells, the suppression of migration activity was 50%, while the inhibition of proliferation was only about 25% (Fig. S3). Thus, ITGA6 is more strongly associated with migration in this condition.
Discussion
Based on the gene expression pattern analysis, we found that higher expression of ITGA6 is a feature specific to HBV-driven HCC and not HCC induced by other causes. Although ITGA6 is found in many types of cancer, we showed that HBx activation in HBV-infected hepatocytes and non-HBV HCC cells induced overexpression of ITGA6 and formation of integrin
Integrins are heterodimeric structures that are made of
In our experiments, treatment of Hep3B and HepG2 cells with laminin and HBx enhanced migration. The increase in migration after treatment with HBx was more prominent in HepG2 cells than in Hep3B cells. As Hep3B cells are an HBV-carrying cell line, it is likely that the effect of HBx is weaker in this cell line. Furthermore, HepG2, a non-HBV HCC cell line, showed markedly increased cellular migration after the addition of HBx. Based on these results, it is possible that HBx closely correlates with the aggressiveness of HCC, as shown previously [35, 36, 37]. In addition, knockdown of ITGA6 in HBx-expressing cells inhibits cellular migration and proliferation to the level of HBx-untransfected cells. This means that ITGA6 may be closely related to the activity of HBx. However, the 2 to 3 week delay between administration of HBx and induction of ITGA6 suggests that increase in ITGA6 may be caused by reorganization of the intracellular network rather than a direct effect of HBx. As discussed, laminin has important functions in the growth and development of HCC [29, 32]. However, preventing and reducing laminin attachment to HCC cells is impossible in this context. The siRNA specific for ITGA6 prevented laminin from attaching to integrins
Conclusions
We demonstrated for the first time a relationship between ITGA6, laminin, and HBx. In addition, we revealed that knockdown of ITGA6 inhibits migration of HCC cells by inhibiting integrins
Footnotes
Acknowledgments
The authors would like to thank Dr. Eun Young Cho in Wonkwang university for providing HBx plasmid and Dr. Dae Ho Lee in Gachon University for providing microarray data in HBx mouse. This study was supported by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (HA17C0039) and National Research Foundation of Korea (NRF-2016R1D1A1B039 30490).
Supplementary data
The supplementary files are available to download from
